- Home
- DXYZ vs PHAR Comparison
DXYZ vs PHAR Comparison
Compare DXYZ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXYZ | PHAR |
|---|---|---|
| Founded | N/A | 1988 |
| Country | | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.6M | 1.1B |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXYZ | PHAR |
|---|---|---|
| Price | $30.80 | $18.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | N/A | ★ 24.5K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ N/A | $3,041.40 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | N/A | $7.50 |
| 52 Week High | N/A | $18.30 |
Technical Indicators
Market Signals| Indicator | DXYZ | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 58.10 |
| Support Level | $30.07 | $16.98 |
| Resistance Level | $33.62 | $17.00 |
| Average True Range (ATR) | 3.09 | 0.69 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 28.53 | 82.04 |
Price Performance
Historical ComparisonAbout DXYZ Destiny Tech100 Inc.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.